A STUDY TO SEE THE EFFECT OF TWO DRUGS, SUCCINYLCHOLINE AND ROCURONIUM IN ELECTROCONVULSIVE THERAPY.

A RANDOMIZED, SINGLE BLINDED, PARALLEL GROUP COMPARATIVE STUDY OF SAFETY AND EFFICACY OF SUCCINYLCHOLINE AND ROCURONIUM AS NEUROMUSCULAR BLOCKING AGENT FOR ELECTROCONVULSIVE THERAPY.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2012/03/002521

Enrollment

100

Registered

2012-03-27

Start date

Unknown

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- SEVERE DEPRESSION.BIPOLAR DISORDER.SCHIZOPHRENIA Health Condition 2: F01-F99- Mental, Behavioral and Neurodevelopmental disorders

Interventions

Intervention1: rocuronium, succinylcholine: neuromuscular blocking agent Intervention2: rocuronium: Inj. Rocuronium 0.25 mg/kg intravenously after inj. Thiopentone sodium2.5 mg/kg for the Eletroconvu

Eligibility

Inclusion criteria

Inclusion criteria: POSTED FOR ELECTROCONVULSIVE THERAPY

Exclusion criteria

Exclusion criteria: 1.NEURO MUSCULAR DISORDER 2.HEART DISEASE. 3.HYPERTENSION. 4.HISTORY OF DRUG ALLERGY. 5.DIFFICULT INTUBATION. 6. HIGHER RISK OF ASPIRATION. 7.CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Design outcomes

Primary

Measure	Time frame
ONSET OF ACTION, SEIZURE DURATION, RECOVERY TIME, HEART RATE,SYSTOLIC BLOOD PRESSURE,DIASTOLIC BLOOD PRESSURE AND SATURATION OF ARTERIAL BLOODTimepoint: ONSET OF ACTION, SEIZURE DURATION, RECOVERY TIME, HEART RATE,SYSTOLIC BLOOD PRESSURE,DIASTOLIC BLOOD PRESSURE AND SATURATION OF ARTERIAL BLOOD WITHIN 15 - 20 MIN OF PROCEDURE	—

Secondary

Measure	Time frame
recovery of patient from psychiatric disorderTimepoint: 6-8 weeks of therapy	—

Countries

India

Contacts

Public ContactDR JAIMIN PANDYA

GOVERNMENT MEDICAL COLLEGE,BHAVNAGAR

trivedi_lopa@yahoo.in09428009958

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026